Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus deferred Moderna bivalent Omicron booster in previously vaccinated adults
ACTRN12622000411741Phase 2Completed
- Sponsor
- University of Melbourne
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Melbourne. Primary endpoint: Proportion with Omicron neutralizing antibody titre >1:100 in immediate vaccination group. Started Nov 2022; status: completed.
02
Drugs
elasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12622000411741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000411741.